Quote, ohm20: "But the one thing new is a wondr
Post# of 148256
(Total Views: 647)
Posted On: 12/13/2022 1:26:33 PM
Quote, ohm20:
"But the one thing new is a wondrous thing. The results from the one macaque treated with AAV leronlimab is even greater than it appears. A functional cure for HIV would be amazing. What about other long term diseases Long Covid, ME/CFS, Alzheimer's, Parkinson's, ALS, diabetes, recurrent cancers and so many more. Only one shot to help long suffering patients would be a blessing.
With just one subject in the study only scientists and doctors focusing on HIV are paying attention. Once a multi-subject study is done and the clinical holds are lifted proving safety that news should become widespread on HIV.
The future: The downside is that very long term HIV trials would need to be conducted to prove out safety in a drug that completely alters the immune system. Meanwhile Cytodyn can conduct it's other trials, gain approval and build up a war chest on it's 2031 expiration patent. Part of that war chest can be used to license the AAV patent from OHSU and will have further protection via that patent farther into the future."
OK, let that sink in for a minute. A single subject in the study has been tested after treatment with leronlimab and there is evidence that the drug is blocking the HIV replication, thus a potential cure. And this treatment may be effective for many other diseases!
This is a very big deal.
"But the one thing new is a wondrous thing. The results from the one macaque treated with AAV leronlimab is even greater than it appears. A functional cure for HIV would be amazing. What about other long term diseases Long Covid, ME/CFS, Alzheimer's, Parkinson's, ALS, diabetes, recurrent cancers and so many more. Only one shot to help long suffering patients would be a blessing.
With just one subject in the study only scientists and doctors focusing on HIV are paying attention. Once a multi-subject study is done and the clinical holds are lifted proving safety that news should become widespread on HIV.
The future: The downside is that very long term HIV trials would need to be conducted to prove out safety in a drug that completely alters the immune system. Meanwhile Cytodyn can conduct it's other trials, gain approval and build up a war chest on it's 2031 expiration patent. Part of that war chest can be used to license the AAV patent from OHSU and will have further protection via that patent farther into the future."
OK, let that sink in for a minute. A single subject in the study has been tested after treatment with leronlimab and there is evidence that the drug is blocking the HIV replication, thus a potential cure. And this treatment may be effective for many other diseases!
This is a very big deal.
(12)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼